[go: up one dir, main page]

GB9420116D0 - A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions - Google Patents

A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions

Info

Publication number
GB9420116D0
GB9420116D0 GB9420116A GB9420116A GB9420116D0 GB 9420116 D0 GB9420116 D0 GB 9420116D0 GB 9420116 A GB9420116 A GB 9420116A GB 9420116 A GB9420116 A GB 9420116A GB 9420116 D0 GB9420116 D0 GB 9420116D0
Authority
GB
United Kingdom
Prior art keywords
compensating
effects
multiple sclerosis
damage caused
drug treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9420116A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB9420116A priority Critical patent/GB9420116D0/en
Publication of GB9420116D0 publication Critical patent/GB9420116D0/en
Priority to DE69528773T priority patent/DE69528773T2/en
Priority to JP8512415A priority patent/JPH10508583A/en
Priority to ES95933488T priority patent/ES2184808T3/en
Priority to DK95933488T priority patent/DK0784476T3/en
Priority to PL95319830A priority patent/PL181802B1/en
Priority to ZA958391A priority patent/ZA958391B/en
Priority to PT95933488T priority patent/PT784476E/en
Priority to GB9707065A priority patent/GB2308065B/en
Priority to AT95933488T priority patent/ATE227124T1/en
Priority to NZ293642A priority patent/NZ293642A/en
Priority to CZ1997995A priority patent/CZ293873B6/en
Priority to SK438-97A priority patent/SK281932B6/en
Priority to EP95933488A priority patent/EP0784476B1/en
Priority to US08/817,086 priority patent/US6096737A/en
Priority to HU9702373A priority patent/HU225493B1/en
Priority to SI9530626T priority patent/SI0784476T1/en
Priority to AU36126/95A priority patent/AU710339B2/en
Priority to PCT/GB1995/002361 priority patent/WO1996011009A1/en
Priority to CA002200761A priority patent/CA2200761C/en
Priority to FI971290A priority patent/FI116659B/en
Priority to IS4454A priority patent/IS1956B/en
Priority to NO19971539A priority patent/NO314486B1/en
Priority to US09/584,401 priority patent/US6569850B1/en
Pending legal-status Critical Current

Links

GB9420116A 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions Pending GB9420116D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
CA002200761A CA2200761C (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
NZ293642A NZ293642A (en) 1994-10-05 1995-10-05 Prevention or treatment of nerve damage caused by multiple sclerosis and other demyelinating conditions with a tri- or tetracyclic antidepressant or a monoamine oxidase inhibitor and a neurotransmitter-inducer
SK438-97A SK281932B6 (en) 1994-10-05 1995-10-05 USING NEUROTRANSMITER THE COMBINATION OF TRICYCLIC ANTIDEPRESIS OR INHIBITOR OF MONOAMINOOXIDASE WITH AMINO ACID COMPOUND
ES95933488T ES2184808T3 (en) 1994-10-05 1995-10-05 TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMELINIZING STATES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE, THYROSINE OR TRIPTOPHAN AND OPTIONALLY A VITAMIN B12 COMPOSITE.
DK95933488T DK0784476T3 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (MS) and other demyelination conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and optionally a vitamin B12 compound
PL95319830A PL181802B1 (en) 1994-10-05 1995-10-05 Treatment of sclerosis multiplex (sm) an dother demyelination states
ZA958391A ZA958391B (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (MS) and other demyelinating conditions
PT95933488T PT784476E (en) 1994-10-05 1995-10-05 TREATMENT OF MULTIPLE SCLEROSIS (EM) AND OTHER DEMELINIZING CONDITIONS USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE TYROSINE OR TRIPTOFAN AND OPTIONALLY A COMPOUND OF VITAMIN B 12
GB9707065A GB2308065B (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (MS) and other demyelinating conditions
AT95933488T ATE227124T1 (en) 1994-10-05 1995-10-05 TREATMENT OF MULTIPLE SCLERosis (MS) AND OTHER DEMYELINIZATION DISEASES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALAMIN, TYROSINE OR TRYPTOPHAN AND POSSIBLE. A VITAMIN B12 COMPOUND
DE69528773T DE69528773T2 (en) 1994-10-05 1995-10-05 TREATMENT OF MULTIPLE Sclerosis (MS) AND OTHER DEMYELINISATION DISEASES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALAMINE, TYROSIN OR TRYPTOPHANE AND EVTL. A VITAMIN B12 COMPOUND
CZ1997995A CZ293873B6 (en) 1994-10-05 1995-10-05 Medicament for treating multiple sclerosis or other demyelinating conditions
JP8512415A JPH10508583A (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis and other demyelinating conditions using lofepramine containing L-phenylalanine, tyrosine or tryptophan, and preferably vitamin B
EP95933488A EP0784476B1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and optionally a vitamin b 12 compound
US08/817,086 US6096737A (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound
HU9702373A HU225493B1 (en) 1994-10-05 1995-10-05 Use of antidepressants, mao inhibitors and serotonine reuptake inhibitors for the treatment of multiple sclerosis (ms) and other demyelinating conditions
SI9530626T SI0784476T1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and optionally a vitamin b 12 compound
AU36126/95A AU710339B2 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
PCT/GB1995/002361 WO1996011009A1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
IS4454A IS1956B (en) 1994-10-05 1997-03-26 Treatment of multiple sclerosis and other demyelins with lofepramine in combination with L-phenylalanine, tyrosine or tryptophan, and possibly vitamin B12
FI971290A FI116659B (en) 1994-10-05 1997-03-26 Use of Compounds in the Preparation of Drugs for the Treatment of Multiple Sclerosis (MS) and Other Myelin Reduction Conditions
NO19971539A NO314486B1 (en) 1994-10-05 1997-04-04 Use of an antidepressant in combination with phenylalanine or tyrosine for the preparation of medicine for the treatment of multiple sclerosis or other demyelinating conditions, as well as a combination preparation and unit dosage form.
US09/584,401 US6569850B1 (en) 1994-10-05 2000-06-01 Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tyrptophan and possibly a vitamin B12 compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions

Publications (1)

Publication Number Publication Date
GB9420116D0 true GB9420116D0 (en) 1994-11-16

Family

ID=10762407

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9420116A Pending GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions

Country Status (2)

Country Link
GB (1) GB9420116D0 (en)
ZA (1) ZA958391B (en)

Also Published As

Publication number Publication date
ZA958391B (en) 1996-05-06

Similar Documents

Publication Publication Date Title
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
AU7545594A (en) Implantable device for the treatment of aedemas
AU2746897A (en) Techniques for treating epilepsy by brain stimulation and drug infusion
SI0730864T1 (en) Medicament for treating cardiac inflammatory diseases
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
GB9410236D0 (en) Cytotoxic drug therapy
AU2806692A (en) Medicament for the treatment of anxiety
HUP9901303A3 (en) A pharmaceutical composition for the treatment of autoimmune diseases
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU6369396A (en) Drug for ameliorating brain diseases
GB9303157D0 (en) Treatment of a group of related disorders
ZA932303B (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
GB9420116D0 (en) A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
ZA932450B (en) Drugs for the treatment of diabetes
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
GB9508482D0 (en) A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
ZA95908B (en) A synergistic formulation for treatment of rheumatic diseases
EP0754037A4 (en) Methods of administering n-substituted benzamides or phenothiazines
CA2188871A1 (en) Method for Treating Psoriasis
AU7383994A (en) Medicaments containing vapiprost hydrochloride for the treatment of inflammatory diseases
AU6097394A (en) Method for the treatment of respiratory disease
GB9304549D0 (en) Apparatus for administration of drugs
GB9324852D0 (en) A medicament for the treatment of metasteses
BG98001U (en) Medicament for the treatment of hyperkeratotic conditions of the skin
AU5532094A (en) Therapeutic agents for the treatment of cachexia